A citation-based method for searching scientific literature

Sarah J Roffey, R Scott Obach, Jenny I Gedge, Dennis A Smith. Drug Metab. Rev. 2007
Times Cited: 115







List of co-cited articles
290 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Determination of mean valproic acid serum level by assay of a single pooled sample.
R A Hamilton, W R Garnett, B J Kline. Clin. Pharmacol. Ther. 1981
123
23

Human radiolabeled mass balance studies: objectives, utilities and limitations.
Natalia Penner, Lewis J Klunk, Chandra Prakash. Biopharm Drug Dispos 2009
50
44


Mass balance studies, with a focus on anticancer drugs.
Jan H Beumer, Jos H Beijnen, Jan H M Schellens. Clin Pharmacokinet 2006
44
31


Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
Karthick Vishwanathan, Kathlene Babalola, Jack Wang, Robert Espina, Linning Yu, Adedayo Adedoyin, Rasmy Talaat, Abdul Mutlib, JoAnn Scatina. Chem. Res. Toxicol. 2009
57
15

Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
Deepak Dalvie, R Scott Obach, Ping Kang, Chandra Prakash, Cho-Ming Loi, Susan Hurst, Angus Nedderman, Lance Goulet, Evan Smith, Hai-Zhi Bu,[...]. Chem. Res. Toxicol. 2009
100
9


Drug metabolites in safety testing.
Thomas A Baillie, Mitchell N Cayen, Hassan Fouda, Ronald J Gerson, James D Green, Scott J Grossman, Lewis J Klunk, Bernard LeBlanc, Darcy G Perkins, Lisa A Shipley. Toxicol. Appl. Pharmacol. 2002
149
8


A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Richard A Graham, Bert L Lum, Glenn Morrison, Ilsung Chang, Karin Jorga, Brian Dean, Young G Shin, Qin Yue, Teresa Mulder, Vikram Malhi,[...]. Drug Metab. Dispos. 2011
37
21


Predicting circulating human metabolites: how good are we?
Shelby Anderson, Debra Luffer-Atlas, Mary Pat Knadler. Chem. Res. Toxicol. 2009
64
10

Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
Graham Lappin, Lloyd Stevens. Expert Opin Drug Metab Toxicol 2008
40
17

Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
Laurent Leclercq, Filip Cuyckens, Geert S J Mannens, Ronald de Vries, Philip Timmerman, David C Evans. Chem. Res. Toxicol. 2009
79
8




Novel MS solutions inspired by MIST.
Ragu Ramanathan, Jonathan L Josephs, Mohammed Jemal, Mark Arnold, W Griffith Humphreys. Bioanalysis 2010
25
24




Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
Robert Espina, Linning Yu, Jianyao Wang, Zeen Tong, Sarvesh Vashishtha, Rasmy Talaat, JoAnn Scatina, Abdul Mutlib. Chem. Res. Toxicol. 2009
58
10

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
J H Beumer, R C Garner, M B Cohen, S Galbraith, G F Duncan, T Griffin, J H Beijnen, J H M Schellens. Invest New Drugs 2007
25
24

From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.
Angus N R Nedderman, Gordon J Dear, Stephanie North, R Scott Obach, David Higton. Xenobiotica 2011
26
23

Validation of isolated metabolites from drug metabolism studies as analytical standards by quantitative NMR.
Gregory S Walker, Tim F Ryder, Raman Sharma, Evan B Smith, Amy Freund. Drug Metab. Dispos. 2011
34
17

Membrane transporters in drug development.
Kathleen M Giacomini, Shiew-Mei Huang, Donald J Tweedie, Leslie Z Benet, Kim L R Brouwer, Xiaoyan Chu, Amber Dahlin, Raymond Evers, Volker Fischer, Kathleen M Hillgren,[...]. Nat Rev Drug Discov 2010
6


Metabolites and safety: What are the concerns, and how should we address them?
Dennis A Smith, R Scott Obach. Chem. Res. Toxicol. 2006
64
7



A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts.
R C Garner, J Barker, C Flavell, J V Garner, M Whattam, G C Young, N Cussans, S Jezequel, D Leong. J Pharm Biomed Anal 2000
38
13


Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development.
Eric G Solon, Alain Schweitzer, Markus Stoeckli, Brendan Prideaux. AAPS J 2010
126
5

Managing the challenge of chemically reactive metabolites in drug development.
B Kevin Park, Alan Boobis, Stephen Clarke, Chris E P Goldring, David Jones, J Gerry Kenna, Craig Lambert, Hugh G Laverty, Dean J Naisbitt, Sidney Nelson,[...]. Nat Rev Drug Discov 2011
220
5

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
David C Evans, Alan P Watt, Deborah A Nicoll-Griffith, Thomas A Baillie. Chem. Res. Toxicol. 2004
349
5



Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs.
William J Guiney, Claire Beaumont, Steve R Thomas, Darren C Robertson, Simon M McHugh, Annelize Koch, Duncan Richards. Br J Clin Pharmacol 2011
17
29

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Theodore R Johnson, Weiwei Tan, Lance Goulet, Evan B Smith, Shinji Yamazaki, Gregory S Walker, Melissa T O'Gorman, Gabriella Bedarida, Helen Y Zou, James G Christensen,[...]. Xenobiotica 2015
26
19

The use of accelerator mass spectrometry to obtain early human ADME/PK data.
Graham Lappin, R Colin Garner. Expert Opin Drug Metab Toxicol 2005
26
15

Application of quantitative NMR in pharmacological evaluation of biologically generated metabolites: implications in drug discovery.
Abdul Mutlib, Robert Espina, Karthick Vishwanathan, Kathlene Babalola, Zecheng Chen, Christoph Dehnhardt, Aranapakam Venkatesan, Tarek Mansour, Inder Chaudhary, Rasmy Talaat,[...]. Drug Metab. Dispos. 2011
13
30


Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites.
Wendy WeiWei Wang, Salman R Khetani, Stacy Krzyzewski, David B Duignan, R Scott Obach. Drug Metab. Dispos. 2010
82
4

A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Don Walker, Joe Brady, Deepak Dalvie, John Davis, Martin Dowty, J Neil Duncan, Angus Nedderman, R Scott Obach, Pat Wright. Chem. Res. Toxicol. 2009
39
10

A regulatory perspective on issues and approaches in characterizing human metabolites.
Karen L Davis-Bruno, Aisar Atrakchi. Chem. Res. Toxicol. 2006
32
12

Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
Philip Timmerman, Morten Anders Kall, Ben Gordon, Sirpa Laakso, Achim Freisleben, Richard Hucker. Bioanalysis 2010
56
7

The use of isotopes in the determination of absolute bioavailability of drugs in humans.
Graham Lappin, Malcolm Rowland, R Colin Garner. Expert Opin Drug Metab Toxicol 2006
48
8


Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).
S Nilgün Cömezoğlu, Van T Ly, Donglu Zhang, W Griffith Humphreys, Samuel J Bonacorsi, Donald W Everett, Marvin B Cohen, Jinping Gan, Jan H Beumer, Jos H Beijnen,[...]. Drug Metab. Pharmacokinet. 2009
11
36


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.